IMCR buy at $4.IMCR is a stock that had a lot of big name investors but it could be ready for a deep dive down to $4 as describe on the chart.
Not a financial advise.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.95 USD
−55.50 M USD
250.39 M USD
48.64 M
About Immunocore Holdings plc
Sector
Industry
CEO
Bahija Jallal
Website
Headquarters
Abingdon
Founded
2021
FIGI
BBG00YYCXFB9
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
$IMCR Pullback Buy SetupI bought this NASDAQ:IMCR pullback buy setup on July 5th and got stopped out for 5% gain.
It is potentially setting put another pullback buy setup.
Previous entry and exit on chart marked as dashes.
IMCR Short [Trend Reversal]Market Phase & Period:
Uptrend. February 2022 - November 2022
Description:
The trend reached its highs in November 2022 but failed to continue in February 2023, making a double top pattern.
The selling pressure observed in February-March 2023 indicates weakness in the bullish momentum, with t
Young biotech leader $IMCR with good VCPImmunocore Holdings is a commercial-stage T cell receptor biotechnology company working to develop and commercialize transformative medicines for oncology, infectious diseases and autoimmune and inflammation diseases.
In a confirmed uptrend, yesterday signaled a good pivot buy where I placed an in
Big sell off on trial results. Oversold perhaps?Investors reacted strongly to the downside on news of the latest trial results, while the companies headline read more bullish.
Going to look at this one as potentially oversold - time will tell of course.
Could look at a stop limit buy order where if the stock recovers then you can enter the trad
$IMCR Box SetupA recent Biotech IPO that could be putting in the bottom of its IPO base. Breaking its downtrend (red line) and volatility contracting and forming a tight box setup. On focus list for next week.
Immunocore Hldgs Plc Ads (IMCR)- DEVELOPS AND MARKETS IMMUNOTHERAPIES WITH T-CELL RECEPTORS TO TREAT C
$IMCR is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Immunocore is a developer of a novel class of TCR (T cell receptor) bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune.
The shar
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.